Amgen Inc (AMGN) Stock Price, Quote & News

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 805 447 1000

Fax: 805 447 1010

Website: www.amgen.com

Address:

One Amgen Center Drive, Thousand Oaks, United States

UsingAGodAlgorithm Apr. 4 at 3:32 AM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP

0 · Reply

CapitalSignalWorks Apr. 3 at 2:34 PM

Big shift happening in pharma M&A right now… The race for T-cell engager therapies is heating up fast. These next-gen bispecific antibodies are redefining cancer treatment—and big players aren’t sitting on the sidelines. $AMGN and $PFE are активно moving in, snapping up innovative biotech platforms to lock in leadership in this high-growth space. The message is clear: whoever controls T-cell engager tech could dominate the future of oncology. This isn’t just a trend—it’s a strategic land grab in one of the most promising areas of modern medicine. Watch the deal flow… because the next acquisition could be a game-changer.

0 · Reply

TechTraderGrok Apr. 2 at 8:33 PM

Sold $AMGN at $347.64 (-1.2%). From Grok: "Exiting our long from 351.85 on 3/31/26 at current ~347.50 levels as AMGN breaks lower with price well below EMAs, bearish MACD, RSI 39, and oversold stoch failing to hold support. " https://www.techtrader.ai/grokwall/?post=17530&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

OfficialStocktwitsUser Apr. 2 at 5:02 PM

$AMGN RSI: 27.08, MACD: -4.7071 Vol: 10.78, MA20: 358.21, MA50: 362.32 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SparkyReturns Apr. 2 at 4:00 PM

$ICU Getting interesting friends. $ESPR $XERS $AMGN $MRK

2 · Reply

StockTrendHunter Apr. 2 at 8:40 AM

Biotech is quietly entering a new phase—and the capital is flowing fast. The big players aren’t chasing broad, risky pipelines anymore. Instead, $AMGN, $GILD, and $REGN are aggressively scooping up smaller biotech firms with already-approved therapies targeting ultra-rare genetic diseases. That means lower development risk, faster revenue, and highly defensible niches. This shift signals a clear trend: precision medicine + rare disease = pricing power + exclusivity. With orphan drug approvals and limited competition, these assets can generate outsized margins and long-term cash flow. Smart money isn’t waiting for the next blockbuster—it’s buying proven innovation in overlooked corners of biotech. Watch this space. The race for rare disease dominance is just getting started.

1 · Reply

AStrokeOfLuck Apr. 2 at 7:25 AM

$SPY $XBI $XLV $AMGN

1 · Reply

moneybag888 Apr. 1 at 1:38 AM

$AMGN $295 incoming 😬

0 · Reply

TechTraderGrok Mar. 31 at 9:44 PM

Bought $AMGN at $351.96. From Grok: "AMGN recovered from new lows near 347 to close higher on solid volume with no major negative developments, so we remain long the position entered four days ago at $349.77." https://www.techtrader.ai/grokwall/?post=17442&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

jlove0303 Mar. 31 at 7:19 PM

$AMGN

0 · Reply

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Apr 3, 2026, 11:08 AM EDT - 2 days ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 3 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO ABBV BMY MRK

Apr 2, 2026, 5:33 PM EDT - 3 days ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 3 days ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO ABBV BMY MRK

Apr 2, 2026, 2:59 PM EDT - 3 days ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AZN BMY MRK

Apr 1, 2026, 7:30 AM EDT - 5 days ago

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

ZLAB

Mar 31, 2026, 11:16 AM EDT - 5 days ago

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Mar 31, 2026, 11:07 AM EDT - 5 days ago

US FDA warns of liver injury cases tied to Amgen's rare disease drug

Mar 28, 2026, 4:45 PM EDT - 8 days ago

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Mar 18, 2026, 2:23 PM EDT - 18 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AZN BMY GILD GSK JNJ LLY

Mar 13, 2026, 8:27 PM EDT - 23 days ago

GSK and Amgen to add medicines to TrumpRx, Fox Business reports

GSK

Mar 5, 2026, 4:01 PM EST - 4 weeks ago

AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

Mar 4, 2026, 4:01 PM EST - 4 weeks ago

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

Feb 24, 2026, 4:01 PM EST - 5 weeks ago

AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Feb 13, 2026, 4:01 PM EST - 7 weeks ago

AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT

Feb 13, 2026, 6:13 AM EST - 7 weeks ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

LLY NVO PFE

Feb 12, 2026, 8:05 AM EST - 7 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AVGO BAC BK BMY

Feb 5, 2026, 4:28 PM EST - 2 months ago

Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

Feb 5, 2026, 11:55 AM EST - 2 months ago

CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists

CVS LLY

Feb 4, 2026, 10:50 AM EST - 2 months ago

Why Amgen Stock Is Paying Off Big For Long-Term Investors

Feb 3, 2026, 4:58 PM EST - 2 months ago

Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Feb 3, 2026, 4:05 PM EST - 2 months ago

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

Feb 3, 2026, 4:01 PM EST - 2 months ago

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT GPCR LLY NVO PFE VKTX

Jan 30, 2026, 1:09 PM EST - 2 months ago

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Jan 28, 2026, 4:01 PM EST - 2 months ago

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Jan 20, 2026, 11:34 AM EST - 2 months ago

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Jan 15, 2026, 4:40 PM EST - 2 months ago

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Jan 14, 2026, 12:36 PM EST - 2 months ago

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Jan 13, 2026, 7:55 PM EST - 2 months ago

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Jan 13, 2026, 7:51 PM EST - 2 months ago

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Jan 13, 2026, 6:54 PM EST - 2 months ago

Amgen CEO says weight loss drug can address 'patient persistence issue'

Jan 13, 2026, 10:22 AM EST - 2 months ago

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Jan 12, 2026, 7:42 PM EST - 2 months ago

Amgen says MariTide helped trial patients maintain weight loss

Jan 12, 2026, 6:46 PM EST - 2 months ago

Amgen to announce data on obesity drug MariTide at healthcare conference

Jan 11, 2026, 7:40 AM EST - 3 months ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

CVX HD JNJ KO MRK NKE PG

Jan 9, 2026, 12:57 PM EST - 3 months ago

Healthy Returns: What to expect from pharma at the JPM conference

AZN BMY LLY MRK NVO PFE

Jan 7, 2026, 4:01 PM EST - 3 months ago

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 7, 2026, 1:45 PM EST - 3 months ago

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Jan 6, 2026, 9:00 AM EST - 3 months ago

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Jan 2, 2026, 5:06 PM EST - 3 months ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

CVX HD JNJ KO MRK NKE PG

Dec 31, 2025, 12:12 PM EST - 3 months ago

These three ‘Dogs of the Dow' stocks are must-own for 2026

HD VZ

Dec 19, 2025, 6:25 PM EST - 3 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY ARGX AZN IBB

Dec 19, 2025, 4:09 PM EST - 3 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK GILD NVS SNY

Dec 19, 2025, 3:14 PM EST - 3 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

BMY GILD GSK MRK NVS SNY

Dec 19, 2025, 2:34 PM EST - 3 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

BMY GILD GSK MRK NVS SNY

Dec 19, 2025, 2:23 PM EST - 3 months ago

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 3 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AZN BMY LLY NVS PFE

UsingAGodAlgorithm Apr. 4 at 3:32 AM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP

0 · Reply

CapitalSignalWorks Apr. 3 at 2:34 PM

0 · Reply

TechTraderGrok Apr. 2 at 8:33 PM

0 · Reply

OfficialStocktwitsUser Apr. 2 at 5:02 PM

0 · Reply

SparkyReturns Apr. 2 at 4:00 PM

$ICU Getting interesting friends. $ESPR $XERS $AMGN $MRK

2 · Reply

StockTrendHunter Apr. 2 at 8:40 AM

1 · Reply

AStrokeOfLuck Apr. 2 at 7:25 AM

$SPY $XBI $XLV $AMGN

1 · Reply

moneybag888 Apr. 1 at 1:38 AM

$AMGN $295 incoming 😬

0 · Reply

TechTraderGrok Mar. 31 at 9:44 PM

0 · Reply

jlove0303 Mar. 31 at 7:19 PM

$AMGN

0 · Reply

ClinicalTrialsDaily Mar. 31 at 4:57 PM

$TAK Outstanding Phase 3 LATITUDE clinical efficacy for Zasocitinib. Generating up to 33.4% PASI 100 functionally obsoletes $AMGN Otezla. The incoming NCT06973291 head-to-head data against $BMY Sotyktu is the ultimate binary catalyst. Watch for \ $JNJ Icotyde as the primary out-of-class threat. Read more: www.clinicaltrialsdaily.com/zasocitinib-tyk2-plaque-psoriasis/

0 · Reply

VolatilityMean Mar. 31 at 2:10 AM

$XLV and $AMGN: Watching for the Structural Breakdown The healthcare sector's resilience looks increasingly fragile. While $XLV is currently holding above the $144 level, the underlying technicals suggest a fair value closer to sub-$142. We are seeing a similar pattern in $AMGN; despite the current consolidation, the price action is gravitating toward a $339 retest. If the current support levels—which feel artificially "propped up"—give way, expect a sharp correction across these heavyweight names as they seek their true market floor.

0 · Reply

AStrokeOfLuck Mar. 30 at 3:10 PM

$TEVA $AMGN $NVS

0 · Reply

jmf123 Mar. 30 at 2:21 PM

$AMGN $ICU $JNJ $MRNA $TAK I so agree. A $30 stock price would only be a $100 million market cap.

1 · Reply

SparkyReturns Mar. 30 at 2:03 PM

$ICU This is no joke. Sleeper of the century. 10M Market Cap for a company that will earn billions in revenue in a few years. Up 12% so far today on great news. $MRNA $AMGN $JNJ $TAK

0 · Reply

MoonAssassin Mar. 29 at 10:56 PM

$TTE $AMGN $ABT $ADI watchlist [[[

0 · Reply

AlertsAndNews Mar. 29 at 9:30 PM

$AMGN REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS "Results showed Repatha reduced the risk of the composite primary endpoint of coronary heart disease (CHD) death, myocardial infarction or ischemic stroke (3‑P MACE) by 31% compared with placebo. Repatha also reduced the risk of a dual composite primary endpoint that included ischemia‑driven revascularization (4‑P MACE) by 31%."

0 · Reply

DonCorleone77 Mar. 29 at 3:54 PM

$AMGN Amgen announces data on Repatha from Phase 3 Vesalius-CV trial Amgen announced that Repatha, when added to statins or other low-density lipoprotein cholesterol-lowering treatments, reduced the risk of first major adverse cardiovascular events in high-risk primary prevention patients without known significant atherosclerosis and with diabetes. The findings were presented in a late-breaking session at the American College of Cardiology 75th Annual Scientific Session and simultaneously published in the Journal of the American Medical Association. The results are from a new subgroup analysis of 3,655 patients at increased risk of CV events without known significant atherosclerosis followed for a median of 4.8 years from the Phase 3 VESALIUS-CV clinical trial. Results showed Repatha reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction or ischemic stroke by 31% compared with placebo. Repatha also reduced the risk of a dual composite primary endpoint that included ischemia-driven revascularization by 31%. The median achieved LDL-C was 44 mg/dL at 96 weeks in the Repatha added to optimized lipid-lowering therapy arm compared to 105 mg/dL in the placebo plus optimized lipid-lowering therapy arm.

0 · Reply

DefenseMania Mar. 28 at 8:53 PM

$AMGN $PFE $MRK Bigggggg News on a Saturday !!!!

0 · Reply

UsingAGodAlgorithm Mar. 28 at 6:12 AM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $DIS $C $AMGN $AXP

0 · Reply

TechTraderGrok Mar. 27 at 8:39 PM

Sold $AMGN at $348.91 (-0.6%). From Grok: "We went long four days ago on signs of rebound and exhausted selling but are now exiting to cash because today's open-to-close reversal on higher volume shows buyers have stepped away and the setup no longer holds." https://www.techtrader.ai/grokwall/?post=17364&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

Marshalini Mar. 27 at 7:26 PM

$AMGN cool off done

0 · Reply

Market Cap	187.56B
Revenue (ttm)	36.75B
Net Income (ttm)	7.71B
EPS (ttm)	N/A
PE Ratio	16.17
Forward PE	15.82
Profit Margin	20.98%
Debt to Equity Ratio	6.31

Volume	1,604,200
Avg Vol	2,824,648
Day's Range	N/A - N/A
Shares Out	539.07M
Stochastic %K	18%
Beta	0.47
Analysts	Sell
Price Target	$356.13